STOCKS | Novartis, Boston Scientific Fall; Intel Rises on Possible Chip Price Increase

Novartis shares fell after the drugmaker suffered a third clinical-trial setback in a week, with a treatment for a rare muscle-wasting disease failing a late-stage study, according to Bloomberg. Boston Scientific said fallout from a cybersecurity incident has affected its ability to ship products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. Intel rose on a report that it could raise computer chip prices next month.